Gufic Biosciences promotes Shekhar Tarbir Aley to President - Critical Care SBUs, Nepal & Institution
Mumbai: Gufic Biosciences has announced the promotion of Shekhar Tarbir Aley from Senior Vice President - Critical Care SBUs, Nepal & Institution to President - Critical Care SBUs, Nepal & Institution, and continues to be Senior Management Personnel of the Company.
"we wish to inform you that on the basis of recommendation of Nomination & Remuneration Committee, the Board of Directors vide Circular Resolution passed on September 16, 2025 has approved the Promotion and Re-designation of Mr. Shekhar Tarbir Aley as President – Critical Care SBUs, Nepal & Institution, Senior Management Personnel of the Company with effect from September 16, 2025," the company stated in a BSE filing.
Shekhar Aley holds B.SC. Degree in Pure Science & Certifications in people & business management.
He is also pursuing higher studies Doctorate in Business Administration (DBA). He is an experienced pharmaceutical leader with over 30 years of diverse experience in hospital-focused business units, with a deep-rooted specialization in Critical Care therapies.
Known for driving strategic growth in complex, high- dependence segments, he brings a strong blend of scientific engagement, commercial acumen and operational leadership.
In his previous roles, he played a pivotal part in positioning companies as credible partners and trusted solution providers in the critical care business. He successfully built strong relationships with key opinion leaders, business leaders, and leading tertiary as well as secondary care hospitals across India and Nepal by addressing critical clinical challenges.
To capture PAN India small and district town critical care business opportunities under his leadership Prima Care Division was launched. Under his leadership, the division has already achieved notable success with small town critical care practitioners, secondary care hospitals, and nursing homes.
With a strong track record in critical care business development, scientific brand building, key customers’ engagement, people development and cross-functional team leadership, he is well- positioned to lead the the company's Critical Care Division’s into its next phase of transformation and growth.
Next Story